QQ客服 官方微博 反馈留言

	Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study
	Wu, Jian-Qiu; Song, Yong-Ping; Su, Li-Ping; Zhang, Ming-Zhi; Lis, Wei; Hu, Yu; Zhang, Xiao-Hong; Gao, Yu-Huan; Niu, Zuo-Xing; Feng, Ru
刊名	CHINESE MEDICAL JOURNAL
	2018
卷号	131期号:15
关键词	Asian Hematopoietic Malignancy Hepatitis B Virus Observational Study Rituximab
ISSN号	0366-6999
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3535798
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Wu, Jian-Qiu,Song, Yong-Ping,Su, Li-Ping,et al. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study[J]. CHINESE MEDICAL JOURNAL,2018,131(15).
APA	Wu, Jian-Qiu.,Song, Yong-Ping.,Su, Li-Ping.,Zhang, Ming-Zhi.,Lis, Wei.,...&Feng, Ji-Feng.(2018).Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.CHINESE MEDICAL JOURNAL,131(15).
MLA	Wu, Jian-Qiu,et al."Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study".CHINESE MEDICAL JOURNAL 131.15(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。